Targets › KISS1R
1 program from 1 company in 3 trials: 2 Phase 2, 1 Phase 1; Infectious disease, Metabolic and endocrine; next expected readout May 2028.
Receptor for kisspeptins (kisspeptin-10, kisspeptin-13, kisspeptin-14 and metastin/kisspeptin-54). The hypothalamic KISS1/KISS1R signaling system plays a central role in the regulation of the hypothalamic-pituitary-gonadal reproductive axis by modulating the secretion of gonadotropin-releasing hormone (GnRH) from GnRH neurons. (UniProt, Q969F8)
Open in Phaseline: the race on KISS1R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Stephanie B. Seminara, MD | Kisspeptin 112-121 (Metastin 45-54) GPR54 (KISS1R) agonist | KISS1R | Phase 2 | Hypogonadotropic Hypogonadism; Hypothalamic Amenorrhea; Reproductive Disorder | May 2028 |
Hypogonadotropic Hypogonadism (1) Hypothalamic Amenorrhea (1) Reproductive Disorder (1)
small molecule (1)
Stephanie B. Seminara, MD (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.